Novartis AG is 21.4x more valuable than BridgeBio Pharma, Inc. by market capitalization ($282.64 B vs $13.20 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BBIO | NVS |
|---|---|---|
| Market cap | $13.20 B | $282.64 B |
| US-listed rank | #791 | #47 |
| Revenue (latest FY) | $502.08M | - |
| SEC filings | 777 | 947 |
Novartis AG is 21.4x more valuable than BridgeBio Pharma, Inc. by market capitalization ($282.64 B vs $13.20 B).
Full pages: BridgeBio Pharma, Inc. and Novartis AG, or browse the full rankings.